A claudin-targeting molecule as an inhibitor of tumor metastasis

Rie Saeki1, Masuo Kondoh, Hideki Kakutani

  • 1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.

Insights

Claudin targeting shows promise for inhibiting tumor metastasis. A novel molecule suppressed lung metastasis in mice without apparent side effects, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Tumor metastasis is a primary cause of cancer mortality.
  • Claudin overexpression is common in malignant tumors, but claudin-targeting antimetastasis therapies are unexplored.
  • A claudin-4-targeting molecule (C-CPE-fused PSIF) was previously developed.

Purpose of the Study:

  • To investigate claudin CPE receptors as a target for antimetastasis therapy.
  • To evaluate the efficacy of C-CPE-fused PSIF in preclinical metastasis models.

Main Methods:

  • Utilized a claudin-4-targeting agent, C-CPE-fused PSIF.
  • Employed a murine lung metastasis model using claudin-4-expressing B16 (CL4-B16) cells.
  • Assessed effects on B16 cells and spontaneous metastasis of 4T1 breast cancer cells.

Main Results:

  • C-CPE-fused PSIF suppressed lung metastasis of CL4-B16 cells but not wild-type B16 cells.
  • The agent inhibited tumor growth and spontaneous lung metastasis of 4T1 cells.
  • No significant side effects were observed in treated mice.

Conclusions:

  • Claudin targeting represents a novel strategy for inhibiting certain types of tumor metastasis.
  • C-CPE-fused PSIF demonstrates potential as an antimetastasis therapeutic agent.
  • Further research into claudin-targeted therapies is warranted.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...